Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function

被引:15
作者
Dorn, David P. [1 ]
Bryant, Mary K. [1 ]
Zarzour, Jessica [2 ]
Smith, J. Kevin [2 ]
Redden, David T. [3 ]
Saddekni, Souheil [2 ]
Aal, Ahmed Kamel Abdel [2 ]
Gray, Stephen [1 ]
White, Jared [1 ]
Eckhoff, Devin E. [1 ]
DuBay, Derek A. [1 ]
机构
[1] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Dept Radiol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Sch Publ Hlth, Biostat Div, Birmingham, AL 35294 USA
关键词
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; SURVIVAL; MANAGEMENT; SORAFENIB; TRIALS; DAMAGE; TACE;
D O I
10.1111/hpb.12194
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Transarterial chemoembolization (TACE) is recommended as a treatment for unresectable hepatocellular carcinoma (HCC) in patients with normal underlying liver function. The efficacy of TACE in cirrhotic patients with compromised liver function is unknown. Methods: All 'first' TACE interventions for HCC performed at a single institution from 2008 to 2012 were retrospectively reviewed (n = 190). Liver function was quantified via the Child's score. Tumour necrosis after TACE was quantified via the mRECIST criteria. Results: The 'first' TACE procedures of 100 Child's A and 90 Child's B/C cirrhotic patients were evaluated. As expected, the lab-model for end-stage liver disease (MELD) score was significantly higher in the Child's B/C group. Although the number of tumours were similar between the groups, both the size of the largest tumour and the total tumour diameter were greater in the Child's A group. There were no significant differences in post-TACE tumour necrosis between groups. The median survival after TACE was significantly longer in the Child's A compared with Child's B/C patients (21.9 versus 13.7 months, P = 0.03). Conclusions: TACE appears to be equally efficacious in cirrhotic patients regardless of their Child's classification based upon equivalent mRECIST measures of tumour necrosis. However, inferior survival after TACE was observed in the Child's B/C group.
引用
收藏
页码:648 / 655
页数:8
相关论文
共 28 条
[1]  
Biolato M, 2010, EUR REV MED PHARMACO, V14, P356
[2]   Chemoembolization for hepatocellular carcinoma [J].
Bruix, J ;
Sala, M ;
Llovet, JM .
GASTROENTEROLOGY, 2004, 127 (05) :S179-S188
[3]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[4]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[5]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[6]   Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials [J].
Cammà, C ;
Schepis, F ;
Orlando, A ;
Albanese, M ;
Shahied, L ;
Trevisani, F ;
Andreone, P ;
Craxì, A ;
Cottone, M .
RADIOLOGY, 2002, 224 (01) :47-54
[7]   Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: Evaluation of damage to nontumorous liver tissue-long-term prospective study [J].
Caturelli, E ;
Siena, DA ;
Fusilli, S ;
Villani, MR ;
Schiavone, G ;
Nardella, M ;
Balzano, S ;
Florio, F .
RADIOLOGY, 2000, 215 (01) :123-128
[8]   Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J].
Cho, Hyun Seop ;
Seo, Jong Woo ;
Kang, Yeojin ;
Bae, Eun Jin ;
Kim, Hyun-Jung ;
Chang, Se-Ho ;
Park, Dong Jun .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2011, 15 (05) :714-719
[9]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Llovet, Josep M. ;
Bruix, Jordi .
LANCET, 2012, 379 (9822) :1245-1255
[10]   Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction [J].
Garwood, Elisabeth R. ;
Fidelman, Nicholas ;
Hoch, Sarah E. ;
Kerlan, Robert K., Jr. ;
Yao, Francis Y. .
LIVER TRANSPLANTATION, 2013, 19 (02) :164-173